HDT Bio and UTMB's Breakthrough in CCHF Vaccine Development Earns MCDC Innovation Award

Recognition for Innovation in Biodefense

HDT Bio, a clinical-stage biotechnology firm based in Seattle, has made headlines by receiving the prestigious Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. This accolade highlights the remarkable progress achieved in the development of a vaccine against Crimean-Congo Hemorrhagic Fever (CCHF), known as HDT-321. With rapid advancements in immunotherapy and preventive technologies, HDT Bio stands at the forefront of addressing critical health challenges on a global scale.

The Journey from Concept to Clinical Trials

Recent findings confirm that HDT-321, a leading candidate in biodefense vaccination, has successfully transitioned from rigorous laboratory research into Phase 1 clinical investigation. The MCDC Innovation Prototype Award is an annual recognition that honors outstanding innovations that support medical countermeasures against threats posed by chemical, biological, radiological, and nuclear (CBRN) agents.

CCHF, a viral hemorrhagic fever, poses significant risks worldwide and is particularly troubling as it continues to expand its geographic reach, largely due to climate change that affects tick populations. To combat this emerging threat, HDT Bio collaborated with esteemed institutions, including the National Institute of Allergy and Infectious Diseases (NIH/NIAID) and The University of Texas Medical Branch (UTMB), along with support from the U.S. Department of War. These partnerships led to comprehensive preclinical assessments demonstrating HDT-321’s efficacy against the CCHF virus in trials.

Innovation Behind the Vaccine

The development of HDT-321 utilizes the innovative LION™ delivery platform, which is not only effective but also scalable and deployable under diverse conditions, free from stringent cold chain requirements. This delivery system has shown excellent tolerance in previous clinical studies, emphasizing HDT Bio's commitment to creating vaccines that can be rapidly produced and distributed, especially in times of crisis.

HDT Bio's commitment to rigorous standards was demonstrated by obtaining FDA clearance for an Investigational New Drug application, a crucial step that validates the public safety of HDT-321. Preliminary results from early 2026 reveal a robust safety profile, showcasing its readiness for broad clinical application.

Validation from MCDC

Steve Reed, CEO of HDT Bio, expressed pride in the achievement, stating, "We are honored to receive this recognition from MCDC, which reflects the dedication of our team and the strength of our partnerships with NIH/NIAID, UTMB, and the Department of War." This sentiment underscores the collaborative nature of today's medical advancements, where research and innovation flourish through shared expertise and goals.

Notably, at the same forum, HDT Bio achieved first place in the Health Security Innovation Pitch Challenge, affirming its status as a leader in developing broad-spectrum antiviral programs amid the pressing need for responsive healthcare solutions in light of rising viral outbreaks.

Looking Ahead

As the urgency for effective vaccines grows, particularly against rapidly emerging infections globally, the work being undertaken by firms like HDT Bio is critical. Their research does not just contribute a new vaccine but also a scalable platform aimed at enhancing global health security.

HDT Bio continues to innovate and expand its portfolio, focusing on areas from cancer to infectious diseases, ensuring readiness against current and future health crises. Their advancements serve as reminders of the indispensable role of biotechnology in safeguarding public health.

For more details about their ongoing projects and revolutionary approach to vaccine development, visit HDT Bio. This work is supported by the NIH/NIAID and underlines the dynamic collaboration between government and private sectors in the pursuit of better healthcare solutions.